Targeting Postprandial Hyperglycemia: A Comparative Study of Insulinotropic Agents in Type 2 Diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 11, 2003, Pages 5248-5254

  Carroll, Mary F ^a   Gutierrez, Absalon ^a   Castro, Marygrace ^a   Tsewang, Dechen ^a   Schade, David S ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; GLIPIZIDE; GLUCOSE; INSULIN; NATEGLINIDE; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; FEMALE; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; HEALTH CENTER; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TIME;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; CYCLOHEXANES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GLIPIZIDE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PHENYLALANINE; POSTPRANDIAL PERIOD;

EID: 0345305664     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030649     Document Type: Article

References (31)

1. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, the DIS group 1996 Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583
2. DECODE Study Group, European Diabetes Epidemiology Group 1999 Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621
3. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A 1999 Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Fungata Diabetes study. Diabetes Care 22: 920-924
4. Erlinger TP, Brancati FL 2001 Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 24:1734-1738
5. Monnier L, Colette C, Rabasa-Lhoret R, Lapinski H, Caubel C, Avignon A, Boniface H 2002 Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 25:737-741
6. Avignon A, Radauceanu A, Monnier L 1997 Non-fasting plasma glucose is a better marker of diabetic control then fasting plasma glucose in type 2 diabetes. Diabetes Care 20:1822-1826
7. Dinneen S, Gerich JE, Rizza R 1992 Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 327:707-713
8. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD 1988 Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37:1020-1024
9. Ward WK, Beard JC, Halter JB, Pfeiffer MA, Porte D 1984 Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7:491-502
10. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M, Avogaro A, Tiengo A, Del Prato S 1999 Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48:99-105
11. Wahlin-Boll E, Almer L-O, Melander A 1982 Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokin 7:363-372
12. Carroll MF, Izard A, Riboni K, Burge M, Schade DS 2002 Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. Diabetes Care 25:2147-2152
13. Chung M, Kourides I, Canovatchel W, Sutfin T, Messig M, Chaiken RL 2002 Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate release glipizide in patients with type 11 diabetes mellitus. J Clin Pharmacol 42:651-657
14. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT 1997 Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Diabetes Care 20:597-606
15. Mooradian AD, Albert SG, Bernbaum M, Plummer S 1996 The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM. Diabetes Care 19:883-884
16. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin R, Kourides IA 1994 Comparative efficacy of once-daily controlled-release formulation of glipizide and immediate release glipizide in patients with NIDDM. Diabetes Care 17: 1460-1464
17. Walter YH, Spratt DI, Garreffa S, McLeod JF 2000 Mealtime glucose regulation by nateglinide in type 2 diabetes mellitus. Eur J Clin Pharmacol 56: 129-133
18. ATP channel activity and membrane binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 293:444-452
19. Luzio SD, Anderson DM, Owens DR 2001 Effects of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent na teglinide in healthy subjects. J Clin Endocrinol Metab 86:4874-4880
20. Carroll MF, Izard A, Riboni K, Burge M, Schade DS 2002 Fasting hyperglycemia predicts the magnitude of postprandial hyperglycemia: implications for diabetes therapy. Diabetes Care 25:1247-1248
21. Mokan M, Gerich JE 1992 A simple insulin infusion algorithm for establishing and maintaining overnight near-normoglycemia in type 1 and type 2 diabetes. J Clin Endocrinol Metab 74:943-945
22. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE 2001 Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24:983-988
23. Landgraf R, Bilo JG, Muller PG 1999 A comparison of regaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55:165-171
24. Kitabchi AE, Kaminska E, Fisher JN, Sherman A, Pitts K, Bush A, Bryer-Ash M 2000 Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am J Med Sci 319: 143-148
25. Burge MR, Schmidt-Fiorentino K, Fischette C 1998 A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 279:137-143
26. Abbasi F, Reaven GM 2002 Relationship between fasting and daylong glucose concentrations in diet-treated patients with type 2 diabetes. Metabolism 51: 457-459
27. Boden G, Chen X, Urbain JL 1996 Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 45:1044-1050
28. Bolli GB, Gerich JE 1984 The "dawn phenomenon" - a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 310:746-750
29. Donnan PT, MacDonald TM, Morris AD for the DARTS/MEMO Collaboration 2002 Adherence to prescribed oral hypoglycemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 19:279-284
30. Dezii CM, Kawabata H, Tran M 2002 Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. Southern Med J 95:68-71
31. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D 2002 Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 87:4171-4176